ArticlePakistan journal of medical sciences2026
Diagnostic Significance of Circulating EBV-miR-BHRF1-3 and EBV-miR-BART2-5p in Lymphoma A Case-Control Study.
Article in Pakistan journal of medical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Epstein-Barr virus (EBV)-derived microRNAs (miRNAs) have been proposed as potential circulating biomarkers in EBV-associated malignancies. This study aimed to quantify the expression levels of four EBV-miRNAs (ebv-miR-BHRF1-2-5p, BHRF1-3, BART1-3p, and BART2-5p) in peripheral blood and to explore their possible diagnostic value in distinguishing lymphoma patients from healthy individuals. Methodology: This case control study included 50 newly diagnosed lymphoma patients (22 Hodgkin lymphoma, 28 Non-Hodgkin lymphoma) and 50 healthy controls recruited in 2025 at the Department of Internal Medicine (Hematology), Atatürk University. qRT-PCR analyses were performed at the Department of Medical Biology. EBV-miRNA expression levels were calculated using the ΔCt method with U6 snRNA as an internal control. Statistical analyses included FDR correction and ROC curve evaluation. Results: Ct values for U6 snRNA and all four EBV-miRNAs were significantly lower in lymphoma patients compared with controls (all p < 0.001, FDR < 0.001), indicating increased levels of circulating viral transcripts. ROC analyses showed that some miRNAs, particularly BHRF1-3 and BART1-3p, demonstrated notable discriminatory ability between patients and controls. No significant overall differences were observed between Hodgkin and Non-Hodgkin lymphoma; however, subtype analysis revealed significant variation in BHRF1-3 and BART2-5p expression (FDR = 0.005). Conclusion: Circulating EBV-miRNAs were elevated in lymphoma patients, and several miRNAs showed promising discriminatory performance. However, this study is limited by its single-center design and the absence of external validation. Therefore, these findings should be considered preliminary, and further research in larger and independent cohorts is needed to confirm the diagnostic utility of EBV-derived miRNAs in lymphoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.